BG Technology

Bacterial Ghosts (BGs) are empty, non-living bacterial envelopes of Gram-negative bacteria. They are produced by controlled expression of the cloned bacteriophage gene E, which forms a lysis-tunnel structure within the envelope of living bacteria. The remaining shell is a cell envelope which maintains all surface proteins of the original bacterium in its native state. Although non-living it is therefore the nature of BGs to express all the structural, immunogenic and bio-adhesive properties of the original ancestral bacterium.

​

BGs are highly sophisticated natural micrometer particles mimicking by their surface properties living bacteria and, therefore represent safe and effective candidates for vaccines and tumor therapy.

​

Want to know more about the system?

Our Story

BIRD-C is a pioneer in the applications of cutting-edge BG platform technology, offering scale-able solutions for delivery of biologically active substances (e.g. chemotherapeutic drugs), vaccines and adjuvants against emerging and existing infectious and life threatening diseases with an innovative focus on Bacterial Ghosts Cancer Immunotherapy (BGCI).

​

Founded by Prof. Werner Lubitz in 1998, the company has focused on development of a unique, internationally renowned and proprietary technology platform that allows for the generation of empty bacterial shells, so called Bacterial Ghosts (BGs).

​

Another platform is the production of bacteriophages (virus against bacteria) and their use for the control of bacterial pathogens and related infections.

​

Today BIRD-C engages in contract research and business partnerships for Pharma companies and collaborations with renowned academic research institutions worldwide. It is BIRD-C´s policy to actively support its product development partner and licensees during the product development, evaluation and production process to ensure a successful technology transfer and application of BG-based product.

​

Looking to explore our technology and get involved in a partnership?

Phage Hunting and Production

BIRD-C has the skills and provides optimized phage isolation, identification and characterization of phages for specific bacterial pathogens in veterinary and human medicine or environmental pathogen control. Process development for scalability and formulation of high titer phages as deliverables for customers can be performed as contract research.BIRD-C can also assist in patent protection of newly isolated pathogen-specific phages.

​

Are you interested in this service please contact us.

Rapid Bacterial Detection System (RBDS)

BIRD-C is working on prototype of handheld and stationary RBDS devices available for field, community or hospital use and adapted to customers need. This system based on specific recognition of bacteria by bacteriophages which carry a fluorescent label. RBDS can detect MRSA and/or other pathogenic nosocomial infections well under 30 min.

​

If  you looking for such kind of diagnostic kits, please contact us for more details and read more about the system itself.

Abbas Muhammad

Head of Vaccine Development

“Knowledge is lock, and the key is question”
Questioning the effect of BGs on cancer micro environment lead us to new therapeutic area called Bacterial Ghost Cancer Immunotherapy (BGCI). What we do today here in BIRD-C can improve many peoples tomorrow.

Werner Lubitz

Founder and CEO

"Why is the BG system tickling my mind? BGs provide a toolbox to inspire your imagination. You start with living bacteria (minute space ship particles) in micrometer size which for specific purposes can become furnished with nanometer equipment (e.g. new ligands, antigens, enzymes, drugs, nucleic acids, sensors etc) by genetic engineering or chemical modification"

Mascha Rauscher

Chief Production Officer

“The most unique moments are people asking me about my profession. I am a ghost cook!”

Scientific Advisor for Oncology

Robert Mader, PhD

EuroTransBio (ETB) Project DESCAR granted.

Oct. 1, 2017

The project "scar treatment by restoration of skin structure and elasticity (DESCAR)" is funded by EuroTransBio through FFG - Austria via project number ETB-2017-32, DESCAR.

BIRD-C GmbH entered
into a research and development cooperation with PhagoMed Biopharma GmbH, Vienna Austria.

May 1, 2018

To circumvent the urgent medical need to develop alternatives to antibiotics, PhagoMed is accelerating the reintroduction of Phage therapy into western medicine. For more details please click here.

CanSinoBIO joins hands with BIRD-C to explore BGs based Vaccine Solutions.

June 1, 2019

CANSINO BIOLOGICS INC. (CanSinoBIO) is China’s dynamic bio-tech leader blazing new paths in R&D, manufacturing and commercialisation of vaccine products for human use.
For more details click here.

BIRD-C GmbH entered into a research and development cooperation with ChanPharm GmbH Vienna, Austria.

Jan. 1, 2018

ChanPharm is a spin-off company of the University of Vienna. As a contract research organization (CRO) ChanPharm provides high quality drug screening services.

Publications